Menopause isn't just a biological shift—it's a societal reckoning. The way we talk about it, treat it, and even define it reveals far more about our cultural biases than our medical understanding. When Norah O'Donnell sat down with her doctor, Rachel Rubin, to discuss menopause, it wasn't just about hormones and hot flashes. It was about confronting a system that has long dismissed women's health as an afterthought. What makes this particularly fascinating is how the conversation veers into territory that challenges both scientific norms and gendered expectations. The term 'castration event'—used by Dr. Rubin to describe menopause—feels almost confrontational, like a deliberate act of defiance against the idea that women should just 'endure' this phase of life. But why does such a stark metaphor resonate so strongly? Because it reframes menopause not as a natural process, but as a forced severance from the very systems that once sustained us. It’s a reminder that our bodies are not just biological machines, but symbols of power, control, and identity.
Let’s unpack that 'castration event' analogy. Rubin compares women’s hormonal decline to a gas tank that goes from full to empty, while men’s testosterone levels merely dip to half-tanks. This isn’t just a medical observation—it’s a cultural indictment. Men are allowed to 'top up' their hormones, while women are left to fend for themselves with vague advice about diet, exercise, and 'staying positive.' What many people don’t realize is that this disparity isn’t accidental. It reflects a deeper bias in medicine: the assumption that male physiology is the default, and female health is an exception to be managed rather than understood. The gas tank metaphor also hints at a broader truth: when women lose their hormonal 'fuel,' they’re not just losing estrogen—they’re losing agency, vitality, and the social scripts that once defined their roles. This raises a deeper question: If menopause is a castration event, who or what is doing the castrating? The answer, I think, lies in a combination of biology, patriarchy, and a healthcare system that still treats women as secondary patients.
Then there’s the issue of vaginal hormones and the staggering cost of ignoring them. Rubin’s claim that widespread use could save Medicare $6 billion to $22 billion isn’t just a financial argument—it’s a moral one. Why are we allowing a preventable crisis (urinary tract infections leading to sepsis, hospitalization, and death) to persist when a simple, FDA-approved treatment exists? The answer, again, is deeply rooted in systemic neglect. Fewer than 10% of postmenopausal women use vaginal estrogen, despite its approval by the American Urological Association. This isn’t just a failure of education—it’s a failure of empathy. When we dismiss women’s pain as 'just part of aging,' we’re perpetuating a cycle where their suffering is normalized and their needs are minimized. A detail that I find especially interesting is how this underutilization reflects a broader pattern: women are often denied access to treatments that could improve their quality of life, not because they’re ineffective, but because they’re seen as 'luxuries' rather than necessities.
And then there’s testosterone—a hormone most people assume is strictly for men. Rubin’s point that women produce more testosterone than estrogen is both surprising and revelatory. It challenges the outdated notion that testosterone is somehow 'masculine' or 'aggressive,' when in reality, it’s a cornerstone of both male and female health. The fact that the FDA hasn’t approved a testosterone product for women is not just a regulatory oversight—it’s a reflection of how deeply ingrained gender stereotypes are in medical research. When women take testosterone off-label, as O’Donnell does, they’re not just treating low libido. They’re reclaiming a part of their identity that society has tried to erase. This raises a provocative question: If testosterone can help women feel 'more like themselves,' why is it still stigmatized? The answer, I suspect, has less to do with science and more to do with the fear that empowering women with this knowledge might disrupt the status quo.
What this really suggests is that menopause isn’t just a personal journey—it’s a battleground for power, perception, and progress. The way we talk about it today reveals how much we still have to learn about women’s bodies and the systems that govern them. If you take a step back and think about it, the entire conversation around menopause is a microcosm of larger issues: the undervaluation of women’s health, the persistence of gendered stereotypes in medicine, and the reluctance to confront uncomfortable truths about aging. In my opinion, the real revolution isn’t in finding new treatments—it’s in changing the narrative. We need to stop viewing menopause as a 'problem to be solved' and start seeing it as an opportunity to redefine what it means to be a woman in the second half of life. Because when we stop treating menopause as a castration event, we might finally start treating women like the equals they deserve to be.
